Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 663 | 138 | 508 |
| Samples | 584 | 120 | 453 |
| Peptides | 510 | 87 | 416 |
Function
PIK3C2A · Phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 alpha
The protein encoded by this gene belongs to the phosphoinositide 3-kinase (PI3K) family. PI3-kinases play roles in signaling pathways involved in cell proliferation, oncogenic transformation, cell survival, cell migration, and intracellular protein trafficking. This protein contains a lipid kinase catalytic domain as well as a C-terminal C2 domain, a characteristic of class II PI3-kinases. C2 domains act as calcium-dependent phospholipid binding motifs that mediate translocation of proteins to membranes, and may also mediate protein-protein interactions. The PI3-kinase activity of this protein is not sensitive to nanomolar levels of the inhibitor wortmanin. This protein was shown to be able to be activated by insulin and may be involved in integrin-dependent signaling. [provided by RefSeq, Jul 2008].
Isoforms & Proteins
2 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 482 amino-acid changes on canonical ENST00000265970 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in PIK3C2A · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in PIK3C2A – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 6/40 15% | 0/0 0% |
| Endometrial Carcinoma | 12/42 29% | 37/612 6% |
| T-Cell Non-Hodgkins Lymphoma | 1/26 4% | 0/0 0% |
| Melanoma | 10/210 5% | 71/1899 4% |
| Oral Cavity Carcinoma | 2/54 4% | 0/0 0% |
| Colorectal Carcinoma | 21/143 15% | 57/3239 2% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 3/133 2% |
| Acute Myeloid Leukemia | 2/90 2% | 0/0 0% |
| Bladder Carcinoma | 5/58 9% | 17/956 2% |
| Hodgkins Lymphoma | 2/16 12% | 1/122 1% |
| Glioblastoma | 2/98 2% | 0/0 0% |
| Mesothelioma | 1/62 2% | 3/165 2% |
| Gastric Carcinoma | 5/74 7% | 28/1809 2% |
| Other Solid Cancers | 2/94 2% | 26/1515 2% |
| Biliary Tract Carcinoma | 3/54 6% | 14/950 1% |
| Squamous Cell Lung Carcinoma | 1/57 2% | 13/810 2% |
| Rhabdomyosarcoma | 0/33 0% | 3/171 2% |
| Hepatocellular Carcinoma | 3/46 7% | 25/2210 1% |
| Non-Small Cell Lung Carcinoma | 3/304 1% | 16/1390 1% |
| Thyroid Gland Carcinoma | 0/45 0% | 18/1592 1% |
| Cervical Carcinoma | 1/35 3% | 4/422 1% |
| Small Cell Lung Carcinoma | 0/9 0% | 8/752 1% |
| Germ Cell Tumour | 0/25 0% | 2/169 1% |
| Glioma | 4/52 8% | 16/2127 1% |
| Adrenocortical Carcinoma | 0/3 0% | 1/112 1% |
| Plasma Cell Myeloma | 2/44 5% | 1/305 0% |
| Head and Neck Carcinoma | 3/85 4% | 11/1574 1% |
| Non-Cancerous | 1/104 1% | 6/830 1% |
| Ovarian Carcinoma | 2/109 2% | 6/998 1% |
| Neuroendocrine Tumour | 1/154 1% | 4/577 1% |
Mutation Distribution
Where PIK3C2A is mutated · all tissues, split by cell line vs tissue
How many mutations in PIK3C2A were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 663 mutations in PIK3C2A
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|